Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

• Published in: Chinese journal of cancer research 2023-10, Vol.35 (5), p.526-535
• Main Authors: Zhang, Jianwei, Zhu, Haibin, Shen, Lin, Li, Jie, Zhang, Xiaoyan, Bai, Chunmei, Zhou, Zhiwei, Yu, Xianrui, Li, Zhiping, Li, Enxiao, Yuan, Xianglin, Lou, Wenhui, Chi, Yihebali, Xu, Nong, Yin, Yongmei, Bai, Yuxian, Zhang, Tao, Xiu, Dianrong, Chen, Jia, Qin, Shukui, Wang, Xiuwen, Yang, Yujie, Shi, Haoyun, Luo, Xian, Fan, Songhua, Su, Weiguo, Lu, Ming, Xu, Jianming
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1000-9604; 1993-0631
• DOI: 10.21147/j.issn.1000-9604.2023.05.09

ObjectiveCurrently, pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases (PNELM) receiving surufatinib treatment was unsatisfying. Our objective was to examine the association between radiological characteristics and efficacy/prognosis.MethodsWe enrolled patients with liver metastases in the phase III, SANET-p trial (NCT02589821) and obtained contrast-enhanced computed tomography (CECT) images. Qualitative and quantitative parameters including hepatic tumor margins, lesion volumes, enhancement pattern, localization types, and enhancement ratios were evaluated. The progression-free survival (PFS) and hazard ratio (HR) were calculated using Cox's proportional hazard model. Efficacy was analyzed by logistic-regression models.ResultsAmong 152 patients who had baseline CECT assessments and were included in this analysis, the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters. In the multivariable analysis of patients receiving surufatinib (N=100), those with higher arterial phase standardized enhancement ratio-peri-lesion (ASER-peri) exhibited longer PFS [HR=0.039; 95% confidence interval (95% CI): 0.003-0.483; P=0.012]. Furthermore, patients with a high enhancement pattern experienced an improvement in the objective response ratio [31.3% vs. 14.7%, odds ratio (OR)=3.488; 95% CI: 1.024-11.875; P=0.046], and well-defined tumor margins were associated with a higher disease control rate (DCR) (89.3% vs. 68.2%, OR=4.535; 95% CI: 1.285-16.011; P=0.019) compared to poorly-defined margins.ConclusionsThese pre-treatment radiological features, namely high ASER-peri, high enhancement pattern, and well-defined tumor margins, have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.